Caesars Acquisition (CACQ) 12.09 $CACQ Gambling Stock

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Caesars Acquisition (CACQ) 12.09 $CACQ

Gambling Stock Roundup: Macau Revenues on the Decline; Century Casinos to Buy Apex Casino
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 8:35AM CDT
The last week was quite an eventful one for the gambling industry with gambling revenues in Macau for June plunging lower than expected.
CACQ: 12.09 (+0.52), MPEL: 11.95 (-0.14), WYNN: 89.75 (+0.79), CZR: 6.85 (+0.08), CNTY: 6.35 (+0.30), MGM: 22.96 (-0.02)

Gambling Stock Roundup: Macau Early June Data Positive, Caesars Granted Reprieve
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 3:38PM CDT
Stocks in the gambling industry seem to be looking up with major companies gaining value, possibly buoyed by the announcement of positive Macau revenue trends for early June.
CACQ: 12.09 (+0.52), ISLE: 18.44 (+0.24), BYD: 18.74 (+0.45), MPEL: 11.95 (-0.14), WYNN: 89.75 (+0.79), LVS: 44.13 (+0.57), CZR: 6.85 (+0.08), MGM: 22.96 (-0.02)

Caesars Acquisition posts 1Q profit
Automated Insights - Thu May 05, 4:29PM CDT
LAS VEGAS (AP) _ Caesars Acquisition Co. (CACQ) on Thursday reported first-quarter earnings of $9.2 million.
CACQ: 12.09 (+0.52)

Gambling Stock Roundup: MGM Opens T-Mobile Arena, Las Vegas Sands Pays $9M Fine
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 2:53PM CDT
The gambling sector witnessed moderate share price movement last week
CACQ: 12.09 (+0.52), PNK: 11.03 (-0.09), BYD: 18.74 (+0.45), MPEL: 11.95 (-0.14), WYNN: 89.75 (+0.79), LVS: 44.13 (+0.57), CZR: 6.85 (+0.08), MGM: 22.96 (-0.02)

Isabelle Marcoux, Co-Chair of the Centraide of Greater Montreal's 2016 Campaign
Marketwired - Wed Apr 06, 9:16AM CDT
Transcontinental Inc. (TSX: TCL.A)(TSX: TCL.B) is pleased to announce that Ms. Isabelle Marcoux, Chair of the Board of Directors of Transcontinental Inc., will co-chair the Centraide of Greater Montreal's 2016 campaign, one of the largest annual fund drives to break the cycle of poverty and social exclusion in Montreal. Ms. Marcoux will co-chair the campaign with Mr. Mitch Garber, President and Chief Executive Officer of Caesars Acquisition Company and Chairman of Cirque du Soleil. It will be launched on September 29th at the March of 1,000 Umbrellas.
CACQ: 12.09 (+0.52), TCL-A.TO: 18.20 (+0.45), TCL-B.TO: 18.32 (+0.66)

Caesars Entertainment Corp Careens Closer to Bankruptcy
Travis Hoium, The Motley Fool - Motley Fool - Fri Mar 18, 10:00AM CDT
Image source: Caesars Entertainment. The ongoing saga of Caesars Entertainment Corp 's confusing asset shuffling and bankruptcy took another turn on Wednesday, and this time the company as a whole took a step closer to bankruptcy. When Caesars...
CACQ: 12.09 (+0.52), CZR: 6.85 (+0.08)

Gambling Stock Roundup: Macau Declines Again, Nevada December Sales Up, Las Vegas Sands Q4 Earnings Miss
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 4:49PM CST
The last week was quite an eventful one for the gambling industry with gambling revenues in Macau for January plunging, as expected.
CACQ: 12.09 (+0.52), CHDN: 129.51 (+3.80), WYNN: 89.75 (+0.79), LVS: 44.13 (+0.57), CZR: 6.85 (+0.08)

Gambling Stock Roundup: Macau Records 2nd Yearly Drop, Nevada November Sales Up
Zacks Equity Research - Zacks Investment Research - Mon Jan 04, 3:56PM CST
The last week of 2015 was quite an uneventful one for the gambling industry.
CACQ: 12.09 (+0.52), PENN: 13.77 (+0.05), BYD: 18.74 (+0.45), WYNN: 89.75 (+0.79), LVS: 44.13 (+0.57), CZR: 6.85 (+0.08), MGM: 22.96 (-0.02)

Commit To Buy Caesars Acquisition At $5, Earn 9.5% Annualized Using Options
StockOptionsChannel.com - Tue Dec 08, 10:34AM CST
Investors considering a purchase of Caesars Acquisition Co. stock, but tentative about paying the going market price of $7.43/share, might benefit from considering selling puts among the alternative strategies at their disposal.
CACQ: 12.09 (+0.52)

Caesars Acquisition Company Reports Third Quarter 2015 Results
PR Newswire - Mon Nov 09, 3:00PM CST
Caesars Acquisition Company (NASDAQ: CACQ) today reported the following results for Caesars Growth Partners, LLC ("CGP LLC" for the third quarter 2015. Caesars Acquisition Company ("CAC" was formed to make an investment in CGP LLC, owns 100% of the voting membership units of CGP LLC and accounts for its investment under the equity method.
CACQ: 12.09 (+0.52), CZR: 6.85 (+0.08)

Gambling Stock Roundup: Mixed Q3 at Melco Crown, Iao Kun Group's Rolling Chip Turnover Falls Again
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 2:49PM CST
Melco Crown Entertainment Limited (MPEL) and Century Casinos Inc. (CNTY) both posted third quarter 2015 results with earnings beating the Zacks Consensus Estimate while revenues missed.
CACQ: 12.09 (+0.52), BYD: 18.74 (+0.45), MPEL: 11.95 (-0.14), IKGH: 1.07 (+0.02), WYNN: 89.75 (+0.79), CNTY: 6.35 (+0.30), CZR: 6.85 (+0.08)

Gambling Stock Roundup: Macau Revenues & GDP Plummet, Iao Kun Group's Rolling Chip Turnover Falls Again
Zacks Equity Research - Zacks Investment Research - Tue Sep 08, 5:01PM CDT
Macau gaming monthly revenues fell for the 15th consecutive time while GDP of the region fell for the fourth consecutive quarter. Iao Kun Group Holding Company Limited's (IKGH) rolling chip turnover fell for the eleventh consecutive month.
CACQ: 12.09 (+0.52), ISLE: 18.44 (+0.24), CHDN: 129.51 (+3.80), MPEL: 11.95 (-0.14), IKGH: 1.07 (+0.02), LVS: 44.13 (+0.57), CZR: 6.85 (+0.08)

Gambling Stock Roundup: MGM Resorts, Caesars Entertainment Beat on Earnings, Melco Crown Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 8:04AM CDT
MGM Resorts International's (MGM) earnings and revenues beat the Zacks Consensus Estimate. Melco Crown Entertainment Limited (MPEL) posted dismal results with earnings and revenues missing the same.
CACQ: 12.09 (+0.52), BYD: 18.74 (+0.45), MPEL: 11.95 (-0.14), IKGH: 1.07 (+0.02), CNTY: 6.35 (+0.30), CZR: 6.85 (+0.08), MGM: 22.96 (-0.02)

Caesars Acquisition Company Reports Second Quarter 2015 Results
PR Newswire - Tue Aug 04, 3:01PM CDT
Caesars Acquisition Company (NASDAQ: CACQ) today reported the following results for Caesars Growth Partners, LLC ("CGP LLC" for the second quarter 2015. Caesars Acquisition Company ("CAC" was formed to make an investment in CGP LLC, owns 100% of the voting membership units of CGP LLC and accounts for its investment under the equity method.
CACQ: 12.09 (+0.52), CZR: 6.85 (+0.08)

Gambling Stock Roundup: Earnings in Focus, Macau Revenues Fall 14 Months in a Row - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 03, 3:53PM CDT
Wynn Resorts Ltd. (WYNN) posted dismal second quarter 2015 results with earnings and revenues missing the Zacks Consensus Estimate. Gross gaming revenues from Macau declined for the month of Jul 2015.
CACQ: 12.09 (+0.52), PENN: 13.77 (+0.05), PNK: 11.03 (-0.09), CHDN: 129.51 (+3.80), WYNN: 89.75 (+0.79), CZR: 6.85 (+0.08), MGM: 22.96 (-0.02)

Is It Time to Bet on Caesars Entertainment While the Stock Is Down?
Bradley Seth McNew, The Motley Fool - Motley Fool - Thu Jun 18, 11:03AM CDT
The drama surrounding  Caesars Entertainment continues to unfold as disgruntled creditors continue to pursue legal options against Caesars. On June1, Caesars stock dropped 16% after a judge in New York give a small victory to creditors that shows...
CACQ: 12.09 (+0.52), CZR: 6.85 (+0.08), AAPL: 96.68 (+0.74)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 169

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 337

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 191

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 143

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 154

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 352

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 134

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 0

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 37

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 163

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

BerGenBio Welcomes First Patient in Lung Cancer Study

Updated Category News Views 202

BerGenBio Embarks on Promising Lung Cancer Trial BerGenBio ASA, a clinical-stage biopharmaceutical company dedicated to combating serious diseases through innovative therapies, has reached a significant milestone in its journey. The company has successfully included the first patient in its clinical trial, focusing on the cutting-edge AXL kinase inhibitor known as...

Continue Reading
CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform

Updated Category News Views 247

CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform CIMG Inc. (NASDAQ: IMG), a dynamic group in the digital health and sales development sector, has officially launched its tokenized stock on the FlowStocks platform. This exciting development follows successful testing and represents a significant shift in how the company interacts with its investors. The new...

Continue Reading
Exploring the Impact of New SEC Leadership on Cryptocurrency

Updated Category News Views 179

New Era for Cryptocurrency Under SEC Leadership The recent changes at the Securities and Exchange Commission (SEC) under new leadership signal a transformative period for the cryptocurrency market. These developments could reshape the regulatory landscape, offering clarity and direction for investors and companies involved in the digital asset space. Understanding the...

Continue Reading
Shytoshi Kusama Transitions Roles: Shiba Inu's New Direction

Updated Category News Views 190

Shytoshi Kusama Transitions to New Leadership Role Shytoshi Kusama, the driving force behind the Shiba Inu ecosystem, has made a significant change by stepping down from his role as the lead visionary. This pivotal shift marks a transition to the position of lead ambassador, as he aims to spearhead global adoption more effectively. The Shift in Leadership Announcing his...

Continue Reading
BASF Shares Fall Following Proposed Dividend Cuts to Shareholders

Updated Category News Views 281

BASF (ETR:BASFN) just took a hit on its stock price after announcing some major shifts in its dividend policy. Shares plummeted by 2.9% to €44.035, all thanks to the company's new proposed minimum annual dividend of €2.25 per share for the upcoming 2024 business year. That’s a stark drop from the previous €3.40 per share they dished out in 2023—talk about making...

Continue Reading